Latest Breaking News On - Kentaro tahara - Page 5 : comparemela.com

Sosei Heptares to Regain Full Ownership of GSK4381406*, a

GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesIndependent.

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023. The full report can be found by clicking here. Chris Cargill, President & CEO of Sosei Heptares, commented: “The third quarter has been an exciting and transformational period for the Group following the acquisition of Idorsia’s phar

Sosei Heptares' President & CEO and Head of UK R&D to Participate in a 'Fireside Chat' at the Jefferies London Healthcare Conference 2023

Sosei Heptares' Partner, Pfizer, Progresses Its GLP-1

PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan and.

Sosei Heptares' Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial